SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    De Vries N, Tak PP. The response to anti TNF alpha treatment: gene regulation at the bedside. Rheumatology (Oxford) 2005; 44: 7057.
  • 2
    Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, Salles G. Allele specific binding to the -308 single nucleotide polymorphism site in the tumor necrosis factor-alpha promoter. Eur J Immunogenet 2004; 31: 159.
  • 3
    Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, et al. Secretion of tumor necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 45663.
  • 4
    Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 4016.
  • 5
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 184952.
  • 6
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 7
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 8
    Nogueira NL, Sebbag M, Chapuy-Regaud S, Clavel C, Fournie B, Cantagrel A, et al. Autoantibodies to deiminated fibrinogen are the most efficient serological criterion for the diagnosis of rheumatoid arthritis. Arthritis Res 2002; 4 Suppl 1: A90.
  • 9
    Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, et al. Consensus statement on the initiation and continuation of tumor necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 5045.
  • 10
    Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004; 71: 27480.
  • 11
    Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers of the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 5269.
  • 12
    Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, de Miguel S, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 107782.
  • 13
    Mugnier B, Roudier J. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis [letter]. Arthritis Rheum 2004; 50: 40756.
  • 14
    Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumor necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF-alpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007; 46: 936.
  • 15
    Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of polymorphism at position -857 of the tumor necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 54752.
  • 16
    Jawaheer D, Li W, Graham RR, Chen W, Damle A, Xiao X, et al. Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet 2002; 71: 58594.